Apellis Pharmaceuticals (APLS)
(Delayed Data from NSDQ)
$23.38 USD
+0.25 (1.08%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $23.38 0.00 (0.00%) 7:04 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Fundamental Charts
About Market Cap
As of the previous market close, Apellis Pharmaceuticals, Inc. has a market cap of $2.92B, which represents its share price of $23.13 multiplied by its outstanding shares number of 126.29M. As a mid-cap company, APLS's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
APLS 23.38 +0.25(1.08%)
Will APLS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for APLS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APLS
Apellis Pharmaceuticals (APLS) Reports Q2 Earnings: What Key Metrics Have to Say
Repligen (RGEN) Lags Q2 Earnings Estimates
APLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag
Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli
Other News for APLS
50 Day Moving Average Resistance appears for APLS after 2.9% move
Fell Below 50 Day Moving Average appears for APLS after 2.34% move
Is APLS ready to move higher? 50 Day Moving Average Support shows up after sliding 1.85%
APLS Crosses Below Key Moving Average Level
NR7 appears for APLS after 2.17% move